

**CONFIDENTIAL**



MMM433

**TheraGuide 5-FU™  
Analysis Result**

**PHYSICIAN**  
John Doe MD  
Myriad Genetics, Inc.  
320 Wakara Way  
Salt Lake City, UT 84108

**SPECIMEN**  
Specimen Type: **Blood**  
Draw Date: **Oct 18, 2007**  
Accession Date: **Oct 19, 2007**  
Report Date: **Oct 22, 2007**

**PATIENT**  
Name: **Doe, Jane**  
Date of Birth:  
Patient ID:  
Gender: **Female**  
Accession #: **00254463-BLD**  
Requisition #: **00254463**


**Test Results and Interpretation**

**HIGH RISK**

<u>Genes Analyzed</u>	<u>Results</u>	<u>Interpretation</u>
DPYD	No Variant Detected	No Variant Detected
TYMS	2R/2R	High Risk

DPYD : Dihydropyrimidine dehydrogenase (DPYD) gene analysis identified no mutations. There may be other rare abnormalities at the DPYD locus that are not detected by this analysis.

TYMS : 2R/2R : Thymidylate synthetase (TYMS) gene analysis identified the 2R/2R genotype. In previous studies patients with this genotype have a 2.5-fold increased risk of 5-FU toxicity compared to the general population [2-4].



**Analysis Description :** This test is designed to identify mutations in 23 coding exons and approximately 690 adjacent intronic base pairs of DPYD and also to identify the number of 28 base pair repeats with the 5'UTR region of the TYMS gene.

**Additional Information :** General information about TheraGuide 5-FU™ can be found at [myriadtests.com](http://myriadtests.com). If you have any questions regarding this report, please do not hesitate to contact Medical Services at 1-800-469-7423.

**References:**

- 1. Mol Cancer Ther. 2006; 5(11):2895-2904
- 2. Clin Cancer Res. 2004; 10(17):5880-5888
- 3. Clin Cancer Res. 2006; 12(13):3928-3934
- 4. Pharmacogenomics. 2001; J1:65-70

**Authorized Signature:**

Richard J. Wenstrup, MD Diplomate ABMG Chief Medical Officer	Karla Bowles, Ph.D. Diplomate ABMG Associate Laboratory Director	M. Junaid Shabbeer, Ph.D. Diplomate ABMG Assistant Laboratory Director
Benjamin B. Roa, Ph.D. Diplomate ABMG Laboratory Director	W. Christine Spence, Ph.D. Diplomate ABMG Associate Laboratory Director	John P Tazelaar, MD Diplomate ABP Associate Laboratory Director

The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational in some states. This test was developed and its performance characteristics determined by Myriad Genetics Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.